This prospective observational study will evaluate the safety and effectiveness of Mabthera (Rituximab) within the first 6 months of treatment in patients with severe active rheumatoid arthritis in routine care. For each eligible patient data will be collected for 6 months. Target sample size is <2000 patients.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01071798?cond=%22Arthritis%22&lup_s=10/31/2013&lup_d=30
